July 23, 2021

Latest News on CGM and Dexcom Straight from the CEO, Kevin Sayer

It’s not everyday that you get the offer to interview a diabetes device luminary. So I jumped at the chance to interview Kevin Sayer,chairman, president and CEO of Dexcom for T1D Exchange. Dexcom has, with Continuous Glucose Monitoring technology, led the way in revolutionizing diabetes care for people who take insulin (both T1D and T2D) and many others. Many people with diabetes (and caregivers) consider CGM more critical to keeping their glucose within target range (defined as 70 - 180 mg/dL) than their insulin delivery device. In this interview Sayer shares how Medicare is making CGM more accessible for beneficiaries, when we can expect Dexcom’s next generation G7 CGM, growth in CGM use among people with T2D, and how Dexcom is partnering with other device companies and data analysis platforms. Read it here...